This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines
• All resolutions were approved by 100% of the participating Noteholders and C Warrantholders
• Noteholders representing 99.9% of total outstanding principal amount participated
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.
Novasep Holding S.A.S (“Novasep”), a leading supplier of services and technologies for the life sciences industry, announces the launch of a consent solicitation (the “Consent Solicitation”) in order to, inter alia:
This represents a step forward for the plant-based protein purification industry, with the first compact bed chromatography system for the purification of vegetable proteins.
With this new Viral Vector bioproduction facility, Novasep confirms its leadership position and effectively addresses the growing gene therapy market demand
Novasep’s robust quality assurance system, fully compliant with the highest world standards, showcased during successful FDA inspection of the Chasse-sur-Rhône (France) facility.
BioSC Pilot® is a new tool for continuous and intensified downstream processes in the biopharmaceutical industry.
This facility, located in Seneffe (Belgium), will strengthen Novasep’s drug product services for mAbs, viral vectors and other low volume biopharmaceuticals
Sales are up 4% at 282 M€
EBITDA is up 4.3% at 29 M€